Since other pharmaceuticals with BK channel opener activity are used safely in humans (N’Gouemo, 2011), the class of compounds exemplified by BMS-191011 holds potential for treating individuals with tinnitus. The gene discussed is KCNMA1; the disease is Tinnitus.